NeuroSense Therapeutics Ltd. Deferred Tax Assets, Operating Loss Carryforwards
NeuroSense Therapeutics Ltd. (NRSN) had Deferred Tax Assets, Operating Loss Carryforwards of $8.78 million as of 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $8.78M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $5.69M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $3.31M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $1.65M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $8.78M 20-F · filed 2026-03-31 |
| 2024-12-31 | $5.69M 20-F · filed 2026-03-31 |
| 2023-12-31 | $3.31M 20-F · filed 2025-04-07 |
| 2022-12-31 | $1.65M 6-K · filed 2024-06-17 |
| 2021-12-31 | $717.00K 6-K · filed 2024-06-17 |